A year after Japan brought assisted reproductive technology (ART) under its public health insurance program, multiple pregnancies among ART patients rose to 4,354 cases in 2023 – the highest on record – according to a study drawing on data from the Japan Society of Obstetrics and Gynecology, cited by Japan Today. The 36% jump from 2022 has prompted researchers to question whether the structure of the insurance framework itself is influencing clinical decisions in ways that increase health risk and, by extension, claims exposure across Japan’s health insurance system.
Under the current program, women who began fertility treatment before age 40 are covered for up to six embryo transfers. Those between 40 and 42 are covered for up to three. With coverage capped at a fixed number of cycles, patients – particularly those in older age brackets – appear to be opting for multiple embryo transfers to improve their odds of conception before insurance runs out. Multiple pregnancies carry higher health risks for pregnant women, and the complications they generate, including more demanding perinatal care, feed directly into the public insurance system that covers the treatment in the first place. “The insurance system needs to be reviewed taking into account the potential burden of high-risk pregnancies on perinatal care,” said Ayumu Ito, a lecturer at Toho University, which was involved in the study, as reported by Japan Today.
The Japan Society of Obstetrics and Gynecology has maintained since 2008 that single embryo transfer should be the default clinical approach, with exceptions permitted for women aged 35 or older and those who have not achieved pregnancy after at least two prior attempts. Before that guidance took effect, multiple pregnancies occurred in more than 10% of ART cases. The rate declined steadily and held at approximately 3% between 2014 and the early 2020s. The extension of public insurance coverage in 2022 appears to have reversed that trend. By 2023, the multiple pregnancy rate had climbed to 3.8%, with the increase most pronounced among patients aged 41 and older – the cohort with the fewest covered cycles remaining. Of the 4,354 cases recorded, the majority involved twin pregnancies, while 69 involved triplets and six involved quadruplets.
The pattern points to a coverage design question with direct relevance to public health insurers: when a fixed cycle limit creates financial pressure to complete treatment within a narrow window, patients may make decisions that produce higher-risk outcomes. It is worth noting that the ART coverage in question operates within Japan’s public health insurance system. The extent to which private insurers are exposed to ART-related claims – through supplementary health products, for instance – is not addressed in the available data, and remains an area where further industry analysis would be warranted.
The ART coverage debate sits within a broader demographic context that carries its own implications for Japan’s insurance industry. The country recorded 671,236 births in 2025 – the lowest annual total on record and the 10th consecutive year of decline – according to health ministry data released in early June, as reported by The Japan Times. For life insurers, annuity providers, and long-term care operators, a sustained contraction in the birth cohort means a narrowing pipeline of future policyholders, a pressure that compounds over time across multiple product lines.
The pace of decline, however, showed some moderation. The 2.2% drop from 2024 was considerably shallower than the approximately 5% annual decreases recorded in prior years. Births among women aged 30 to 34 moved against the broader trend, rising from 253,444 in 2024 to 255,665 in 2025. The health ministry attributed this in part to a rise in marriages among women in the 25-to-34 age bracket documented in the previous year’s data.
Japan’s total fertility rate edged down to 1.14 from 1.15 the prior year, extending a long-term decline from 1.76 four decades ago. The Children and Families Agency cited low wages among younger workers, limited opportunities to meet a partner, and the difficulty of balancing employment with child-rearing as contributing factors. Marriage filings rose by roughly 4,000 to 489,119 in 2025, the second consecutive annual increase – a data point relevant to insurers modelling future household formation and dependent coverage demand. Japan’s marriage figures last peaked in 1972 at close to 1.1 million and have trended mostly downward since 2002. The average age at first marriage was 31.0 for men and 29.7 for women.
The national decline does not distribute evenly, a distinction that matters for insurers with geographically concentrated books of business. Thirteen prefectures, including Iwate and Shizuoka, recorded slight increases in their total fertility rates. The health ministry suggested local policy measures may have contributed, though it has not conducted a formal analysis to identify specific causes. Tokyo, which carries the country’s lowest prefectural fertility rate at 0.96, recorded a birth count increase for the first time in a decade – up 857 to 85,064. Kagawa, Toyama, and Ishikawa also posted modest gains. Insurers with heavier exposure in low-fertility urban markets such as Tokyo face a different product and pricing environment than those operating across regional prefectures where demographic trends are marginally more stable.
Deaths in Japan totalled 1,589,489 in 2025, the first year-on-year decrease in five years. Cancer was the leading cause, followed by heart disease and old age. Among younger populations, suicide was the leading cause of death for men aged 10 to 44 and for women aged 10 to 34 – a pattern with direct relevance to group life and income protection underwriting assumptions. The dip in total deaths does not materially alter the structural equation facing Japan’s life and health insurers. With births at a record low and the population continuing to age, the ratio of working-age policyholders to older claimants shifts further in a direction that affects pricing, reserving, and product viability across life, health, and long-term care lines over the medium to long term.
